Clairity Inc.
June 17, 2025
Company Presentation
AI and Digital Health
153B
Clarity is the first FDA authorized prediction tool for breast cancer risk in the next five years. Founded by Dr. Connie Lehman had a breast imaging at a Mass General Hospital and professor of radiology at Harvard, we are poised to transform how tens of millions of women are assessed for risk of future breast cancer development through the power of AI and machine learning with our proprietary platform.
Company HQ City:
Boston
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
Clairity Breast - FDA authorized May 30, 2025
CEO
Jeffrey Luber
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
0
When you expect your next catalyst update?
Commercial launch 2H 2025
What is your next catalyst (value inflection) update?
Sept 2025
Website
www.clairity.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}